These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37508708)

  • 1. Sobrerol: New Perspectives to Manage Patients with Frequent Respiratory Infections.
    Ciprandi G; Varriccchio A
    Children (Basel); 2023 Jul; 10(7):. PubMed ID: 37508708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel approach to respiratory pharmacology--pharmacological basis of cough, sputum and airway clearance].
    Miyata T
    Yakugaku Zasshi; 2003 Dec; 123(12):987-1006. PubMed ID: 14689863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Sobrerol in chronic bronchitis. Comparison of serum and bronchial mucus levels.
    Braga PC; De Angelis L; Bossi R; Scaglione F; Scarpazza G; Allegra L; Fraschini F
    Eur J Clin Pharmacol; 1983; 24(2):209-15. PubMed ID: 6840169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?
    Scaglione F; Petrini O
    Clin Med Insights Ear Nose Throat; 2019; 12():1179550618821930. PubMed ID: 30670922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral neltenexine in patients with obstructive airways diseases: an open, randomised, controlled comparison versus sobrerol.
    Fadda G
    Minerva Med; 2001 Aug; 92(4):269-75. PubMed ID: 11535970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Action of sobrerol on mucociliary transport.
    Allegra L; Bossi R; Braga PC
    Respiration; 1981; 42(2):105-9. PubMed ID: 7313328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term treatment with sobrerol on the exacerbations of chronic bronchitis.
    Castiglioni CL; Gramolini C
    Respiration; 1986; 50(3):202-17. PubMed ID: 3541091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections.
    Albrecht HH; Dicpinigaitis PV; Guenin EP
    Multidiscip Respir Med; 2017; 12():31. PubMed ID: 29238574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Disse B
    Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the activity of the carbocysteine-sobrerol combination on mucus spinnability.
    Distefano SM; Palermo F; Crimi N; Mistretta A; Pamparana F; Messa A
    Int J Clin Pharmacol Res; 1988; 8(1):31-5. PubMed ID: 3284830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
    Dal Negro R; Pozzi E; Cella SG
    Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol.
    Lu CH; Huang YF; Chu IM
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review on sobrerol as a muco-modifying drug: experimental data and clinical findings in hypersecretory bronchopulmonary diseases.
    Braga PC; Allegra L; Bossi R; Scuri R; Castiglioni CL; Romandini S
    Int J Clin Pharmacol Res; 1987; 7(5):381-400. PubMed ID: 3312046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational prospective study comparing mucoactive and antibiotic treament in the management of acute cough from upper respiratory tract infections.
    Zanasi A; Lecchi M; Mazzolini M; Mastroroberto M; Nardi E; Morselli-Labate A
    Minerva Med; 2015 Oct; 106(5):239-246. PubMed ID: 26495821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sobrerol as expectorant in patients with stable chronic respiratory tract infections. A controlled study].
    Shang H; Grosgurin P; Medici TC
    Schweiz Med Wochenschr; 1982 Dec; 112(50):1846-8. PubMed ID: 6760390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation.
    Minozzi S; Pifferi S; Brazzi L; Pecoraro V; Montrucchio G; D'Amico R
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD000022. PubMed ID: 33481250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucoactive agents for airway mucus hypersecretory diseases.
    Rogers DF
    Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacologic approach to airway clearance: mucoactive agents.
    Rubin BK
    Respir Care; 2002 Jul; 47(7):818-22. PubMed ID: 12088552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucoactive drugs.
    Balsamo R; Lanata L; Egan CG
    Eur Respir Rev; 2010 Jun; 19(116):127-33. PubMed ID: 20956181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacologic approach to airway clearance: mucoactive agents.
    Rubin BK
    Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.